A Personalized Mobile Health Program for Type 2 Diabetes During the COVID-19 Pandemic: Single-Group Pre-Post Study.
Ian Yi Han AngKyle Xin Quan TanClive TanChiew Hoon TanJames Wei Ming KwekJoanne TaySue-Anne Ee Shiow TohPublished in: JMIR diabetes (2021)
The personalized mHealth program was feasible, acceptable, and produced significant reductions in HbA1c (P=.004) and body weight (P<.001) in individuals with type 2 diabetes. Such mHealth programs could overcome challenges posed to chronic disease management by COVID-19, including disruptions to in-person health care access.